For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Angiotensin II antagonists - Independent medicine & health information for consumers & professionals Angiotensin II antagonists — medicine information
Latest independent drug information about angiotensin II antagonists and treatments, written and reviewed by experts in Australia.
Angiotensin II antagonists are also known as AIIA, angiotensin II receptor antagonists, A2RA, angiotensin receptor blockers, ARB or sartans.
| Filter by audience: | |
|---|---|
| All | |
| Consumer | |
| Health professional | |
| Researchers & evaluators | |
| Members & stakeholders | |
| Other | |
| Title | Description | Type | Audience  |
Date* |
|---|---|---|---|---|
| Generic losartan (Cozavan) PBS listed for hypertension | Generic losartan (Cozavan) was PBS listed on 1 December 2011. It is the first generic angiotensin II-receptor antagonist to be listed. | Professional publication - NPS RADAR - Brief item | Health Professionals | 2011-12-01 00:00:00 |
| New dual and triple antihypertensive combinations PBS listed — be aware of potential confusion | Restricted PBS listing for olmesartan with amlodipine (Sevikar), and valsartan with amlodipine and hydrochlorothiazide (Exforge HCT) effective 1 November 2010. | Professional publication - NPS RADAR - Brief item | Health Professionals | 2010-11-10 00:00:00 |
| Indicators of Quality Prescribing: 16 | Indicators of Quality Prescribing: Indicator 16 Good Prescribing (Avoiding the ‘Triple Whammy’). This indicator asks practices how many patients are receiving a combination of ACE inhibitors (or angiotensin II-receptor antagonists), diuretics and NSAIDs (including COX-2 selective NSAIDs). | Professional tool - Indicators of quality prescribing | Health Professionals | 2006-02-01 00:00:00 |
| Indicators of Quality Prescribing: 15 | Indicators of Quality Prescribing: Indicator 15 Heart Failure and ACE Inhibitors. This indicator asks practices what percentage of patients with systolic heart failure are not currently prescribed an ACE inhibitor or angiotensin II-receptor antagonist. | Professional tool - Indicators of quality prescribing | Health Professionals | 2006-02-01 00:00:00 |
| Indicators of Quality Prescribing: 12 | Indicators of Quality Prescribing: Indicator 12 Diabetes and ACE Inhibitors. This indicator asks practices what percentage of patients with type 2 diabetes and hypertension and macroalbuminuria or proteinuria have not been prescribed an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II-receptor antagonist. | Professional tool - Indicators of quality prescribing | Health Professionals | 2006-02-01 00:00:00 |
| Case study PH1 report: For pharmacists | Patient reports a persistent cough. She switched from enalapril to irbesartan 3 months ago after suffering a persistent cough. She has type 2 diabetes and hypertension. | Professional activity - Case study report | Health Professionals | 2000-06-01 00:00:00 |
| Case study 5 report: New drugs | Patient with mild hypertension and mildly elevated cholesterol presents with insomnia and anxiety. Consider the appropriateness of a range of drug therapies for this patient. | Professional activity - Case study report | Health Professionals | 1999-12-01 00:00:00 |
| Case study 48 report: Achieving tight blood pressure control | Patient diagnosed with hypertension after elevated readings over several months. Family history of cardiovascular disease. Despite adequate trial of lifestyle changes his BP remains elevated. | Professional activity - Case study report | Health Professionals | 2007-07-01 00:00:00 |
| Case study 40 report: Assessing new evidence | Elderly patient presents for whom you consider prescribing an angiotensin II receptor antagonist for his recently diagnosed heart failure. | Professional activity - Case study report | Health Professionals | 2006-02-01 00:00:00 |
| Case study PH1: For pharmacists | Patient reports a persistent cough. She switched from enalapril to irbesartan 3 months ago after suffering a persistent cough. She has type 2 diabetes and hypertension. | Professional activity - Case study | Health Professionals | 1999-10-01 00:00:00 |
| Case study 5: New drugs | Patient with mild hypertension and mildly elevated cholesterol presents with insomnia and anxiety. Consider the appropriateness of a range of drug therapies for this patient. | Professional activity - Case study | Health Professionals | 1999-12-01 00:00:00 |
| Case study 48: Achieving tight blood pressure control | Patient diagnosed with hypertension after elevated readings over several months. Family history of cardiovascular disease. Despite adequate trial of lifestyle changes his BP remains elevated. | Professional activity - Case study | Health Professionals | 2007-06-01 00:00:00 |
| Case study 40: Assessing new evidence | Elderly patient presents for whom you consider prescribing an angiotensin II receptor antagonist for his recently diagnosed heart failure. | Professional activity - Case study | Health Professionals | 2005-11-01 00:00:00 |
| Case study 65: Optimising blood pressure control | Shelly is a 52-year-old florist who comes to see you concerned about her blood pressure (BP) readings. | Professional activity - Case study | Health Professionals | 2010-09-01 00:00:00 |
| NPS News 9: Improvements in prognosis and management of heart failure patients | Therapies which improve prognosis and management of patients with heart failure, including non-pharmacological interventions and drugs such as spironolactone, beta-blockers and angiotensin II receptor antagonists. | Professional publication - NPS News | Health Professionals | 2000-04-01 00:00:00 |
| Systolic heart failure - improving treatment | Outlines ways to improve treatment of systolic heart failure. Angiotensin-converting enzyme (ACE) inhibitors and heart failure specific beta blockers can reduce morbidity and mortality in people with systolic heart failure. | Professional publication - NPS News | Health Professionals | 2011-10-04 00:00:00 |
| NPS Prescribing Practice Review 6: Managing hypertension | Information on blood pressure targets and the optimal selection of antihypertensives depending on an individuals level of risk and compelling indications for use. | Professional publication - Prescribing Practice Review | Health Professionals | 1999-11-01 00:00:00 |
| Heart failure - improving treatment | Information on diagnosing heart failure and managing associated risk factors, along with the use of ACE inhibitors, diuretics, beta-blockers and non-drug interventions as treatment. | Professional publication - Prescribing Practice Review | Health Professionals | 2011-11-01 00:00:00 |
| Angiotensin II receptor antagonists: unrestricted PBS listing | Reviews new unrestricted PBS listing of candesartan, eprosartan, irbesartan, and telmisartan for hypertension, heart failure, and diabetic nephropathy. | Professional publication - NPS RADAR - Review | Health Professionals | 2005-08-01 00:00:00 |
Information on this website is published by NPS — an independent, evidence based, not-for-profit organisation funded by the Australian Government Department of Health and Ageing.
NPS develops its information under the guidance of experts in their field, editorial panels, expert reviewers and consumers. Find out more about how we develop our content.
Date published: 2010-12-17 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
